Dyslipidemia in Obesity: Mechanisms and Potential Targets
Open accessThe DOI matches its Crossref record; 166 of the 169 references it cites were found in a registry or an index; 5 of the 56 sources its claims cite were checked for support.
Abstract
Obesity has become a major worldwide health problem. In every single country in the world, the incidence of obesity is rising continuously and therefore, the associated morbidity, mortality and both medical and economical costs are expected to increase as well. The majority of these complications are related to co-morbid conditions that include coronary artery disease, hypertension, type 2 diabetes mellitus, respiratory disorders and dyslipidemia. Obesity increases cardiovascular risk through risk factors such as increased fasting plasma triglycerides, high LDL cholesterol, low HDL cholesterol, elevated blood glucose and insulin levels and high blood pressure. Novel lipid dependent, metabolic risk factors associated to obesity are the presence of the small dense LDL phenotype, postprandial hyperlipidemia with accumulation of atherogenic remnants and hepatic overproduction of apoB containing lipoproteins. All these lipid abnormalities are typical features of the metabolic syndrome and may be associated to a pro-inflammatory gradient which in part may originate in the adipose tissue itself and directly affect the endothelium. An important link between obesity, the metabolic syndrome and dyslipidemia, seems to be the development of insulin resistance in peripheral tissues leading to an enhanced hepatic flux of fatty acids from dietary sources, intravascular lipolysis and from adipose tissue resistant to the antilipolytic effects of insulin. The current review will focus on these aspects of lipid metabolism in obesity and potential interventions to treat the obesity related dyslipidemia.
Overview
CoChat Summary
TL;DR
This narrative review describes how obesity-related insulin resistance, impaired triglyceride lipolysis, increased free fatty acid flux, and altered apolipoprotein/complement metabolism produce the characteristic dyslipidemia of high triglycerides, small dense LDL, and low HDL-C. It summarizes lifestyle and pharmacological approaches, emphasizing weight loss, statins, fibrates, niacin, omega-3 fatty acids, and apoB/non-HDL-C as treatment targets.
Key findings
- The hallmark of obesity dyslipidemia is elevated fasting and postprandial TG, small dense LDL, low HDL-C, and normal or slightly increased LDL-C, with increased apoB; hypertriglyceridemia may be the major cause of the other lipid abnormalities.
- Mechanisms include insulin resistance with enhanced hepatic FFA flux, hepatic overproduction of apoB-containing lipoproteins, reduced LPL mRNA in adipose tissue and LPL activity in skeletal muscle, elevated apo C-III, increased CETP-mediated lipid exchange, hepatic lipase action, and reduced LDL receptor expression; ASP mRNA expression in visceral adipose tissue is reduced by approximately 40% in obese and morbidly obese subjects versus lean controls.
- Atherogenic features include small dense LDL with a five-day residence time and chylomicron remnants that contain approximately 40 times more cholesterol per particle than LDL; postprandial hyperlipidemia with atherogenic remnants is especially linked to visceral obesity.
- Treatment findings include: weight loss of 4–10 kg reduced LDL-C by 12% and increased LDL receptor mRNA by 27%; moderate weight loss of approximately 10% reduced postprandial TG by 27%–46%; fibrates reduce TG by approximately 30%, LDL-C by 8%, and increase HDL-C by an average of 9%; niacin lowers TG by 15%–35% and raises HDL-C by 10%–25%; omega-3 fatty acids reduce plasma TG by 25%–30%; ezetimibe gives an additional 20% LDL-C lowering.
Methods
- Narrative review of lipid metabolism in obesity, including general lipoprotein metabolism, obesity-induced changes, FFA/inflammation interplay, lifestyle interventions, and pharmacological treatment.
- No primary data or study sample; the paper synthesizes published literature and cites prior studies, including metabolic ward studies, stable isotope studies, randomized trials, and meta-analyses.
- Main analysis is qualitative synthesis; no systematic search strategy, meta-analysis, or formal quality assessment is described.
Limitations
- The paper does not explicitly state limitations of the review itself. It notes evidence gaps, including that specific data on niacin plus statins in obesity remain scarce, that increasing HDL-C by exercise remains controversial, and that controversy exists about fibrate therapy on top of statin therapy.
- Evident from the text: as a narrative review, it lacks a described systematic search, inclusion criteria, or formal risk-of-bias assessment, and it reports no primary outcomes of its own.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
4 Valid · 0 Not valid · 28 Not checked · 6 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Visceral obesity leads to insulin resistance in part mediated by adipokines and free fatty acids (FFA).”
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 1. Introduction
What the sources say
- Supportedcites [2] Flock, 2011, Effects of adiposity on plasma lipid response to reductions in dietary saturated fatty acids and cholesterol, Adv. Nutr. source
The “Potential mechanisms altering lipid metabolism” section says excess adipose tissue leads to insulin resistance and identifies circulating adipokines and fatty acids as contributors. The “Weight reduction improves insulin sensitivity and LDL uptake” section specifically links abdominal adiposity with insulin resistance. Page numbers are not available in our copy. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The amount of liberated FFA from chylomicrons and VLDL depends on the activity of LPL, which is stimulated by insulin [17,18].”
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 2. Overview of Lipoprotein Metabolism
What the sources say
- Partly supportedcites [17] Karpe, 2011, Fatty acids, obesity, and insulin resistance: Time for a reevaluation, Diabetes sourceExperimental — accuracy not yet measured
Karpe et al. (2011) support the first half of the sentence: in FATTY ACIDS AND METABOLIC PHYSIOLOGY they state that 'Lipoprotein lipase (LPL) in the capillaries of adipose tissue hydrolyses circulating TG, mainly the dietary fat carried in the chylomicrons,' that VLDL-TG is likewise hydrolysed by LPL, and that 'the lower LPL activity leaves more TG unlipolysed in the triglyceride-rich lipoproteins' — i.e. the amount of fatty acid liberated depends on LPL activity. However, no passage of our copy (searched: LPL stimulated by insulin, insulin action on adipose LPL/activity, LPL activity determining fatty acid release) states that LPL activity is stimulated by insulin; the only acute LPL activation described is by heparin ('Heparin releases LPL from its endothelial binding sites and also activates the enzyme,' PATHOPHYSIOLOGY), and insulin's role in the paper is antilipolytic suppression of fat mobilization (METABOLIC PHYSIOLOGY). The insulin-stimulation clause attributed to this source is therefore not supported. (LLM, conf=0.75)
- Supportedcites [18] McQuaid, 2011, Downregulation of adipose tissue fatty acid trafficking in obesity: A driver for ectopic fat deposition?, Diabetes source
The Abstract (CONCLUSIONS) of our copy states in its own voice that 'In the postprandial period, insulin stimulates fat deposition into adipose tissue. This occurs by hydrolysis of chylomicron triglycerides (TGs) by lipoprotein lipase (LPL) bound to capillary endothelium', i.e. insulin drives the LPL-mediated liberation of fatty acids from TG-rich lipoproteins. The Discussion adds that LPL mediates lipolysis of both chylomicron and VLDL-TG and that postprandial upregulation of adipose tissue LPL occurs in lean but not obese subjects, consistent with insulin stimulation of LPL activity. This is background framing in the cited paper rather than its own experimental measurement, but our copy clearly treats the topic as stated. (LLM, conf=0.80)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recently, it has been described that ASP mRNA expression in visceral adipose tissue is reduced by approximately 40% in obese and morbidly obese subjects with or without insulin resistance when compared to lean controls [50].”
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 4. Interplay between FFA Metabolism and Inflammation in Obesity: Crossroad between Innate Immunity and Lipid Metabolism
What the sources say
- Partly supportedcites [50] Tinahones, 2011, Adipose tissue gene expression of factors related to lipid processing in obesity, PLoS One sourceExperimental — accuracy not yet measured
The Results state that visceral adipose tissue C3/ASP mRNA expression was higher in lean controls than in every obese group. But Table 2 shows reductions of about 44% in obese subjects and 49% in morbidly obese subjects with low insulin resistance, versus about 23% in the morbidly obese high-insulin-resistance/T2DM group. Thus, the approximately 40% reduction does not describe all the groups claimed. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“It is widely recognized that plasma FFA are elevated in obese people as a consequence of an increased fatty acid release from adipose tissue and a reduction in plasma FFA clearance [85,86,87].”
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 4. Interplay between FFA Metabolism and Inflammation in Obesity: Crossroad between Innate Immunity and Lipid Metabolism
What the sources say
- Not checked yetcites [85] Bjorntorp, 1969, Plasma free fatty acid turnover rate in obesity, Acta Med. Scand. source
- Not checked yetcites [86] Mook, 2004, In vivo regulation of plasma free fatty acids in insulin resistance, Metabolism source
- Not checked yetcites [87] Verseyden, 2004, Addition of glucose to an oral fat load reduces postprandial free fatty acids and prevents the postprandial increase in complement component 3, Am. J. Clin. Nutr. source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“The exchange of TG from these remnants for cholesterol-esters from HDL by CETP with the concerted action of hepatic lipase, ultimately leads to the formation of small dense LDL [48,49].”
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 3. Obesity Induced Changes in Lipoprotein Metabolism and Atherogenic Effects
What the sources say
- Not checked yetcites [48] Capell, 1996, Compositional differences of LDL particles in normal subjects with LDL subclass phenotype A and LDL subclass phenotype B, Arterioscler Thromb. Vasc. Biol. source
- Not checked yetcites [49] Hokanson, 1995, LDL physical and chemical properties in familial combined hyperlipidemia, Arterioscler. Thromb. Vasc. Biol. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
14 more claims
Create a free account to see all 38 claims and to verify the 51 references still open.
- It may state two separate claims as one. 18
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated leptin and cholesterol levels are characteristic of obesity, and therefore these results further demonstrate the extent of the obese phenotype observed in Abi3–/– mice (Klop et al., 2013; Obradovic et al., 2021).”
From Deletion of the Alzheimer’s disease risk gene Abi3 locus results in obesity and systemic metabolic disruption in mice (2022) · cites this paper as Klop et al., 2013
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It is common for individuals afflicted with obesity to exhibit changes in the makeup of their circulating plasma fats, a condition known as dyslipidemia. This typically includes elevated levels of apolipoprotein B (apoB), diminished levels of high-density lipoprotein, and alterations in low-density lipoprotein’s particle composition (LDL).”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [51]
In the citing paper
“Obesity has a clear correlation with the incidence of cardiovascular disorders including hypertension, coronary artery disease, heart failure and sudden death”
In the citing paper
“many patients with insulin resistance, the main etiology of T2DM, tend to have high triglyceride and low HDL levels [53,54,55]”
In the citing paper
“Chronically elevated serum cholesterol, particularly LDL, contribute to the degenerative accumulation of plaques in the arteries, which can lead to progressive narrowing or blocking of blood vessels (Klop et al., 2013).”
From Population genomics reveal recent speciation and rapid evolutionary adaptation in polar bears (2014) · cites this paper as Klop et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 3. Obesity Induced Changes in Lipoprotein Metabolism and Atherogenic Effects
“the increased TG content within the LDL is hydrolyzed by hepatic lipase, which leads to the formation of small, dense LDL particles.”
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 3. Obesity Induced Changes in Lipoprotein Metabolism and Atherogenic Effects
“Hypertriglyceridemia further induces an increased exchange of cholesterolesters (CE) and TG between VLDL and HDL and low density lipoproteins (LDL) by cholesterylester-transfer-protein (CETP). This leads to decreased HDL-C concentrations and a reduction in TG content in LDL.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 2. Overview of Lipoprotein Metabolism
“Within the circulation, the HDL particles also become enriched with cholesterol-esters by the action of cholesterylester-transfer-protein (CETP) and phospholipid transfer protein (PLTP).”
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 2. Overview of Lipoprotein Metabolism
“In this process HDL acquires TG from TG-rich lipoproteins in exchange for cholesterol-esters as a direct consequence of the CETP action [11].”
Citations
Cites
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 2×
“However, there is controversy about the effectiveness of fibrate therapy on top of statin therapy since the ACCORD trial was unable to confirm a beneficial effect on cardiovascular endpoints by fenofibrate combined with statins in diabetic patients [156].”
BackgroundMechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814 · cited 1×
“All these mechanisms have been related to the higher incidence of cardiovascular disease seen in obesity [82].”
BackgroundWaist circumference as a measure for indicating need for weight management
Lean, M. E. J., Han, T. S., & Morrison, C. E. (1995) · BMJ · doi:10.1136/bmj.311.6998.158 · Cited by 1,869 · cited 1×
“It has been shown that diurnal triglyceridemia in obese subjects correlates better to waist circumference than to body mass index [78,80], which is in agreement with the hypothesis that the distribution of adipose tissue modulates postprandial lipemia [81].”
ResultNiemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577
Tabas, I., Williams, K. J., & Borén, J. (2007) · Circulation · doi:10.1161/circulationaha.106.676890 · Cited by 1,399
Goldstein, J. L., & Brown, M. S. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.179564 · Cited by 1,344 · cited 1×
“In contrast, LDL is primarily taken up by the liver via the LDL receptor [31,32].”
BackgroundRelation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state
Patsch, J. R., Miesenböck, G., Hopferwieser, T., Mühlberger, V, Knapp, E., Dunn, J. K., Gotto, A. M., & Patsch, W. (1992) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.12.11.1336 · Cited by 1,122
Fatty acids, obesity, and insulin resistance: Time for a reevaluation
Karpe, F., Dickmann, J. R., & Frayn, K. N. (2011) · Diabetes · doi:10.2337/db11-0425 · Cited by 896 · cited 2×
“insulin resistance as seen in obesity [17].”
Background
Cited by
Jung, U., & Choi, M.-S. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15046184 · Cited by 1,880
Samson, S. L., & Garber, A. J. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.09.009 · Cited by 746
Vekic, J., Zeljkovic, A., Stefanovic, A., Jelic-Ivanovic, Z., & Spasojevic-Kalimanovska, V. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.005 · Cited by 612
Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut
Joyce, S. A., MacSharry, J., Casey, P. G., Kinsella, M., Murphy, E. F., Shanahan, F., Hill, C., & Gahan, C. G. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323599111 · Cited by 604
“Reductions of this magnitude are likely to be physiologically relevant for the mammalian host (20).”
BackgroundEffects of Exercise to Improve Cardiovascular Health
Pinckard, K., Baskin, K. K., & Stanford, K. I. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00069 · Cited by 446
Metadata
- Authors
- Klop, B., Elte, J., & Cabezas, M.
- Affiliations
- Sint Franciscus Gasthuis (NL)
- Corresponding author
- Cabezas, Manuel
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2013-04-12
- Volume
- 5
- Issue
- 4
- Pages
- 1218-1240
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC3705344
- OpenAlex
- W1985399572
- Cited by
- 1,665
- References
- 169
- Citations by year
- 2026: 90 · 2025: 157 · 2024: 194 · 2023: 210 · 2022: 196 · 2021: 195 · 2020: 138 · 2019: 117 · 2018: 76 · 2017: 74 · 2016: 75 · 2015: 63 · 2014: 65 · 2013: 12
- FWCI
- 10.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- obesity, dyslipidemia, metabolic syndrome, insulin resistance, small dense LDL, postprandial hypertriglyceridemia, apolipoprotein B, hepatic lipogenesis, adipose tissue inflammation, endothelial dysfunction, cardiovascular risk, lipid metabolism, obesity treatment
- MeSH terms
- Hypolipidemic Agents, Humans, Insulin Resistance, Lipids, Obesity, Risk Factors, Biomarkers, Comorbidity, Treatment Outcome, Inflammation Mediators, Caloric Restriction, Risk Reduction Behavior, Dyslipidemias, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dyslipidemia in Obesity: Mechanisms and Potential Targets. https://app.cochat.ai/papers/10.3390/nu5041218
- The paper
- Klop, B., Elte, J., & Cabezas, M. (2013). Dyslipidemia in Obesity: Mechanisms and Potential Targets. Nutrients. https://doi.org/10.3390/nu5041218
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.